Different T cell subsets in the nodule and synovial membrane: Absence of interleukin-17A in rheumatoid nodules

Arthritis and Rheumatism

Volumn 58, Issue 6, 2008, Pages 1601-1608

  Stamp, Lisa K ^a   Easson, Andrea ^b   Lehnigk, Ulrike ^b   Highton, John ^b   Hessian, Paul A ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17A; INTERLEUKIN 17B; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 6; RNA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RNA ISOLATION; SYNOVIUM; T LYMPHOCYTE SUBPOPULATION;

AGED; CELL DIFFERENTIATION; COHORT STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; RHEUMATIC NODULE; RHEUMATOID NODULE; RNA; SYNOVIAL MEMBRANE; T-LYMPHOCYTE SUBSETS;

EID: 45349099110     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23455     Document Type: Article

References (50)

1. Ziff M. The rheumatoid nodule. Arthritis Rheum 1990;33:761-7.
2. Gabriel SE, Crowson CS, Maradit Kremers H, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
3. Highton J, Palmer DG, Smith MD, Hessian PA. Phenotypic markers of lymphocyte and mononuclear phagocyte activation within rheumatoid nodules. J Rheumatol 1990;17:1130-6.
4. Highton J, Kean A, Hessian PA, Thomson J, Rietveld J, Hart DN. Cells expressing dendritic cell markers are present in the rheumatoid nodule. J Rheumatol 2000;27:339-46.
5. Hessian PA, Highton J, Kean A, Sun CK, Chin M. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003;48:334-8.
6. Highton J, Hessian PA, Stamp L. The rheumatoid nodule: peripheral or central to rheumatoid arthritis? [editorial]. Rheumatology (Oxford) 2007;46:1385-7.
7. dim, CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:844-54.
8. Dolhain RJ, Ter Haar NT, Hoefakker S, Tak PP, de Ley M, Claassen E, et al. Increased expression of interferon (IFN)-γ together with IFN-γ receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br J Rheumatol 1996;35:24-32.
9. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell functions in rheumatoid arthritis? Immunol Cell Biol 2004;82:1-9.
10. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005;19:180-4.
11. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
12. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.
13. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
14. Veldhoen M, Hocking R, Atkins C, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89.
15. H17 and regulatory T cells. Nature 2006;441:235-8.
16. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-36.
17. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007;26:371-81.
18. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Matteson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7.
19. Acosta-Rodriguez EV, Napolitani G, Lanzavecchua A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.
20. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007;56:2936-46.
21. Hoeve MA, Savage ND, de Boer T, Langenberg DM, de Waal Malefyt R, Ottenhoff TH, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006;36:661-70.
22. H17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74.
25. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179:7128-36.
26. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002;169:642-6.
27. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15:985-95.
28. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
29. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α by human macrophages. J Immunol 1998;160:3513-21.
30. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13.
31. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
32. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
33. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
34. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
35. Koenders MI, Lubberts E, Oppers-Walgreen B, van der Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005;167:141-9.
36. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE Study Cohort). Arthritis Rheum 2006;54:1122-31.
37. Highton J, Hung N, Hessian P, Wilsher M. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology (Oxford) 2007;46:811-4.
38. Murphy C, Langrish C, Chen Y, Blumenschein W, McClanahan T, Kastelein R, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
39. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-κB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007;46:57-64.
40. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-γ regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007;56:1145-51.
41. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
42. Orozco G, Rueda B, Robledo G, Garcia A, Martin J. Investigation of the IL23R gene in Spanish rheumatoid arthritis cohort. Hum Immunol 2007;68:681-4.
43. Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K, et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008;67:248-50.
44. Wikaningrum R, Highton J, Parker A, Coleman M, Hessian PA, Roberts-Thomson PJ, et al. Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 1998;41:1783-97.
45. Baeten D, De Keyser F, Veys EM, Theate Y, Houssiau FA, Durez P. Tumor necrosis factor α independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis 2004;63:489-93.
46. Elewaut D, De Keyser F, De Wever N, Baeten D, Van Damme N, Verbruggen G, et al. A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis 1998;57:480-6.
47. De Keyser F, Elewaut D, Overmeer-Graus JP, van den Broek P, Rijnders AW, Veys EM. Dominant T cell receptor rearrangements in IL-2 expanded lymphocytes from rheumatoid nodules suggest antigen driven T cell activation in situ. J Rheumatol 1997;24:1685-9.
48. Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 2007;56:89-100.
49. + T cells partially through STAT3-dependent mechanism. J Immunol 2006;177:5377-85.
50. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;178:2589-98.